Tech Stock Sails to Top of Nasdaq on Buyout Buzz

AQST stock, meanwhile, is fresh off a record low

Stocks are looking for their first win of the week ahead of the Thanksgiving holiday. Among individual names making big moves are drug delivery technology expert Aquestive Therapeutics Inc (NASDAQ:AQST), Israel-based satellite firm Ability Inc (NASDAQ:ABIL), and roofing expert Beacon Roofing Supply, Inc. (NASDAQ:BECN). Here's a quick look at what's moving shares of AQST, ABIL, and BECN.

Court Ruling Levels Aquestive Therapeutics

A U.S. appeals court approved the sale of Dr. Reddy's Laboratories (RDY) generic version of Indivior's opioid treatment, Suboxone Film, sending the shares of Aquestive Therapeutics -- a supplier for Indivior -- down 23.5% at $10.09, fresh off a record low of $9.45. Heading into today's trading, the stock had been holding above steadfast support in the $14.00-$15.00 range since its late-July initial public offering (IPO), but it's now down 37% from its July 25 open at $15.05.

Analysts could soon be ready to re-evaluate their bullish outlooks. All four analysts covering AQST maintain a "buy" or better rating, while the average 12-month price target price target of $28.75 is a 178.6% premium to current trading levels.

Ability Stock Has More Than Doubled Today

Ability stock has more than doubled today -- up 126.2% at $6.38, and the best stock on the Nasdaq -- after the company said it's purchasing its main cellular interception system supplier. The security gapped to an annual high of $14.55 in late June, before pulling back to its recent floor near $3.

Beacon Roofing Supply Stock Rallies Into Familiar Resistance

Beacon Roofing Supply shares are popping today on news the company signed a share purchasing agreement with CD&R Boulder. At last check, BCEN is up 17.5% to trade at $32.97. However, today's upside is running out of steam near the equity's 60-day moving average, a trendline that's ushered the shares to a 48.2% year-to-date deficit.

Analysts, meanwhile, are mixed toward the roofing name, with seven maintaining a "strong buy" rating and nine calling the stock a "hold" or worse. Just today, Wells Fargo upgraded BECN stock to "market perform" from "underperform," while Evercore ISI downgraded the equity to "in line" from "outperform," and lowered its price target to $32 from $48.